The specific purpose of this study is to obtain data on safety and efficacy of combination
chemotherapy with Temozolomide and Topotecan in patients with CNS metastases of solid tumors.
Up to 35 patients will be accrued over 2-3 years and followed for up to 5 years and will
receive 8 cycles of chemotherapy. The primary endpoint is the determinant median overall
survival and progression-free survival of this regimen, time to progression of the brain
metastases, and assessment of toxicity levels in this regimen.